Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 19/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 11/20 | 0.46 |
| ▸ | FAP | Q12884 | 6/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 10/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10057509 | 0.86 | DPP4 (0.45) | DPP4DPP8DPP9FAPDPP7 | |
| Hydrochloric Acid SCHEMBL14973418 | 0.83 | DPP4 (0.49) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL10057508 | 0.82 | DPP4 (0.52) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL10057505 | 0.78 | DPP4 (0.56) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL10057507 | 0.77 | DPP4 (0.51) | DPP4DPP8DPP9FAPDPP7 | |
| Hydrochloric Acid SCHEMBL14973572 | 0.76 | DPP4 (0.51) | DPP4DPP8DPP9FAPDPP7 | |
| Hydrochloric Acid SCHEMBL14973464 | 0.76 | DPP4 (0.69) | DPP4DPP8DPP9FAPDPP7 | |
| Trifluoroacetic Acid SCHEMBL572193 | 0.75 | DPP4 (0.53) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL14982920 | 0.74 | DPP4 (0.41) | DPP4DPP8DPP9FAPDPP7 | |
| Hydrochloric Acid SCHEMBL14973582 | 0.71 | DPP4 (0.40) | DPP4DPP8DPP9FAPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137852-A1 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | Cadila Corporate Campus (IN) | 2013-05-30 | — | — | US | disclosed |
| US-20130137852-A1 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | Cadila Corporate Campus (IN) | 2013-05-30 | — | — | US | disclosed |
| WO-2012017391-A2 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | CADILA PHARMACEUTICALS LIMITED (IN) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137852-A1 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.